Skip to content

Host-pathogen Interaction in Otitis Media

Thorough Clinical Investigation of the Host-pathogen Interaction in Chronic and Recurrent Otitis Media

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00847756
Acronym
OMVac
Enrollment
179
Registered
2009-02-19
Start date
2008-04-30
Completion date
2011-07-31
Last updated
2011-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Otitis Media

Keywords

Otitis media, demography, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, rhinovirus, children, 0-5 years of age, diagnosed rAOM, COME or CSOM by an otorhinolaryngologist, primary and secondary hospital Nijmegen, the Netherlands

Brief summary

Otitis Media (OM) is one of the most frequent diseases in childhood and the primary reason for children to visit a physician. In many countries it is the most common reason to prescribe antibiotics leading to increased drug-resistance of the causative agents, or to undergo surgery. Costs for general health care are expanding, and are estimated to be 3-5 billion dollar annually in the United States. Prevention is suspected to be an important solution to this problem. Although OM management has no universal standard yet, it may imply watchful waiting, antibiotic treatment, adenoidectomy, insertion of tympanostomy tubes and (future) vaccination. Approximately 80% of the acute otitis media (AOM) cases is self-limiting within 2-14 days and also otitis media with effusion (OME) resolves spontaneously: 60% of newly detected OME resolves within 3 months. However, in a significant part of the OM population persistent or recurrent episodes of OM are responsible for a significant morbidity for both children and parents, despite variable treatment options. Through the set up of a new prospective cohort in a clinical setting, relevant patient characteristics, the role of bacterial and viral pathogens, the role of recurrent infection in relation to biofilm formation, and the host response at protein level will be studied in detail. This project is expected to increase the understanding of the underlying mechanisms of OM disease, which will support future treatment and prevention strategies. Better understanding in OM pathogenesis is warranted in order to develop these novel preventive strategies.

Interventions

OTHERquestionnaire

Identification of risk factors

PROCEDUREblood sample

venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.

PROCEDUREcollection of middle ear fluid

During routine surgery middle ear fluids are collected per patient.

PROCEDUREnasopharyngeal swab

A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.

Sponsors

Radboud University Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 5 Years
Healthy volunteers
No

Inclusion criteria

* children up to 5 years of age * suffering from rAOM, COME or CSOM * waiting for tympanostomy tube insertion * informed consent

Exclusion criteria

* No informed consent * The child has a malignancy, or organ transplantation, or immune deficiency in the medical history * The child had recent elective ear surgery (i.e. mastoidectomy, implants \<2 weeks ago) * The child suffers from systemic infectious diseases (i.e. hepatitis, chickenpox)

Design outcomes

Primary

MeasureTime frame
Detection of biological markers in blood which inform us about the risk of recurrent infection and severity of disease01-06-2009 to 01-06-2010

Secondary

MeasureTime frame
Otitis media demography15-04-2008 to 01-01-2010
Bacterial and viral pathogen detection15-04-2008 to 01-01-2010
Determination of the molecular and cellular immune response in relation to viral and bacterial pathogens15-04-08 to 01-01-2010
Gene expression profiling of the three major bacterial pathogens: S. pneumoniae, H. influenzae and M. catarrhalis01-06-2009 to 01-06-2010

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026